AUSTRALIANS with a newly defined type of metastatic breast cancer, HER2-low, will now have access to a life-prolonging drug under the PBS from 01 Sep.
The expanded listing of Enhertu (trastuzumab deruxtecan) will offer a new treatment option for those with unresectable or metastatic breast cancer, which cannot be surgically removed or has spread to other parts of the body.
"While survival outcomes for patients with metastatic breast cancer have improved over the past 20 years, too many will still die prematurely due to the disease," commented commented Monash Health A/Prof, Michelle White.
"The listing of Enhertu is a significant step forward in the management of HER2-low metastatic breast cancer.
"This targeted treatment aims to stop the growth and progression of the disease and provides another effective option for eligible patients," added White.
The PBS expansion for the drug is expected to benefit around 1,700 Australians annually.
Without the subsidy, the cost of a course of Enhertu could exceed $160,000, according to the Department of Health.
With the PBS listing, eligible patients will pay a maximum of $31.60 per script, or $7.70 with a concession card.
Federal Health Minister Mark Butler reaffirmed the government's commitment, saying, "we are making medicines cheaper and more accessible, providing lifesaving options for those fighting this insidious disease".
The sentiment was supported by Vicki Durston, Director of Policy, Advocacy and Support Services at Breast Cancer Network Australia, who said, "Enhertu offers new hope to those with HER2-low metastatic breast cancer, providing an option that was previously unaffordable". JG
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Aug 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Aug 24
